Tips from Other Journals

Influenza Vaccine 1997–1998: An Overview and Comparison



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1998 Feb 15;57(4):858.

A new intramuscular trivalent influenza vaccine is available for the current influenza season. Except for one new antigen (H1N1 antigen), the antigen mix in the current vaccine is the same as last year's. Although it was anticipated that a new nasal spray flu vaccine would be available this year, it has not yet received approval from the U.S. Food and Drug Administration. Consultants from the Medical Letter on Drugs and Therapeutics review current data for the new influenza vaccine.

Influenza vaccination is recommended for elderly and other high-risk patients, their household contacts and health care personnel who may be in contact with them. The vaccination of healthy working adults and children may prevent household spread of the disease. Pregnant women can be vaccinated safely. There is an increased risk of influenza complications in women in the second and third trimesters of pregnancy.

Outbreaks of influenza usually reach a peak between late December and early March and may continue into the spring in some areas. Following vaccination, protection from influenza generally begins one to two weeks after injection and may last six months or longer. Elderly persons may not maintain serum antibody levels for six months and may fall below protection levels in four months or less. The optimal time for influenza vaccination is from October through mid-November, but vaccination any time from September to the end of the influenza season is appropriate.

Dosage recommendations differ for adults and children. A single intramuscular 0.5-mL dose of the vaccine is recommended for adults and for children who are at least three years of age. Children from six to 35 months of age should receive a dose of 0.25 mL. Children younger than nine years of age receiving the vaccine for the first time should receive two doses at least four weeks apart.

Because the influenza vaccine is made from inactivated virus grown in eggs, hypersensitivity reactions can occur, although they are rare. Occasionally, soreness may persist for one to two days at the injection site. Fever, myalgia and malaise can last one or two days but usually occur in young patients with no previous exposure to influenza antigens. Some reactions in children can be averted by administering split-virus and purified-surface-antigen formulations (see the accompanying table).

Comparison of Influenza Vaccines

Vaccine Preparation Available forms* Cost†

Fluzone

Whole virus‡

Vial

$32.50

Split virus

Vial

32.50

10 syringes

42.50

FluShield

Split virus

Vial

38.50

10 syringes

50.00

Fluvirin

Purified surface

Vial

34.50

10 syringes

47.00


*—Each vial contains 5 mL (10 doses); syringes are sold in boxes of 10, each containing one 0.5-mL dose.

†—Estimated cost to the pharmacist based on average wholesale prices, rounded to the nearest half dollar, in Red book. Montvale, N.J.: Medical Economics Data, 1997. Cost to the patient will be higher, depending on prescription filling fee.

‡—Not recommended for use in children.

Adapted with permission from Influenza vaccine, 1997–1998. Med Lett Drugs Ther 1997;39(1009):85–6.

Comparison of Influenza Vaccines

View Table

Comparison of Influenza Vaccines

Vaccine Preparation Available forms* Cost†

Fluzone

Whole virus‡

Vial

$32.50

Split virus

Vial

32.50

10 syringes

42.50

FluShield

Split virus

Vial

38.50

10 syringes

50.00

Fluvirin

Purified surface

Vial

34.50

10 syringes

47.00


*—Each vial contains 5 mL (10 doses); syringes are sold in boxes of 10, each containing one 0.5-mL dose.

†—Estimated cost to the pharmacist based on average wholesale prices, rounded to the nearest half dollar, in Red book. Montvale, N.J.: Medical Economics Data, 1997. Cost to the patient will be higher, depending on prescription filling fee.

‡—Not recommended for use in children.

Adapted with permission from Influenza vaccine, 1997–1998. Med Lett Drugs Ther 1997;39(1009):85–6.

Consultants from the Medical Letter recommend influenza vaccination for high-risk persons and the elderly, their household contacts and health care workers. Adverse reactions are rare and can usually be averted by altering the dosage recommendations.

Medical Letter Consultants. Influenza vaccine, 1997–1998. Med Lett Drugs Ther. 1997:39(1009):85–6.


Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

Navigate this Article